NR vs. Nicotinamide: What Is the Difference for Eye Health?

If you have been reading about NAD+ and eye health, you have likely run into two names that sound almost identical: nicotinamide riboside (NR) and nicotinamide (also called niacinamide). Both raise NAD+ levels. Both belong to the vitamin B3 family. Both appear in research on optic nerve health.

So what is actually different between them, and does it matter for your eyes?

The answer is yes, and the distinction is more meaningful than most supplement marketing lets on. This article breaks down how each molecule works, what the research says, and why Sight Guard uses NR specifically.

They Are Both Vitamin B3, But They Are Not the Same Molecule

Vitamin B3 is not a single compound. It is a family of related molecules your body can convert into NAD+ (nicotinamide adenine dinucleotide), the coenzyme that fuels cellular energy production and DNA repair. The three most common forms:

•       Niacin (nicotinic acid): The oldest form, used historically to manage cholesterol. Causes a well-known skin-flushing reaction.

•       Nicotinamide (NAM): Chemically distinct from niacin. No flushing. "Nicotinamide" is used in research and supplements; "niacinamide" is used in skincare. Same molecule regardless of name.

•       Nicotinamide riboside (NR): NR is nicotinamide with a ribose sugar attached, which changes how it enters cells and how efficiently it converts to NAD+.

These are meaningfully different compounds, not just naming variations.

The Pathway Difference: Why It Matters

Both molecules ultimately become NAD+, but they take different routes.

Nicotinamide enters what is called the salvage pathway. It goes through several enzymatic steps before it can be used to make NAD+. This is a longer, more indirect route.

NR enters through the NRK pathway (nicotinamide riboside kinase pathway). Because NR is structurally closer to NAD+, it requires fewer conversion steps and is generally considered a more direct precursor.

Multiple human studies using 300 mg to 1,000 mg of NR have confirmed it reliably increases NAD+ concentrations in peripheral blood.

The Sirtuin Inhibition Issue

At high doses, nicotinamide has been shown to inhibit sirtuins, a family of enzymes that regulate DNA repair, inflammation, and cellular stress responses. Sirtuins require NAD+ to function, so the goal of taking an NAD+ precursor is partly to keep sirtuin activity robust. Paradoxically, high-dose nicotinamide can blunt this effect.

NR does not appear to share this limitation. Because it enters the NAD+ pathway through a different route, NR can raise NAD+ levels without the sirtuin-inhibiting effect observed with high-dose nicotinamide.

What Does the Eye Health Research Actually Say?

Nicotinamide has real eye health research behind it. The landmark 2017 Williams et al. study in Science used nicotinamide to protect retinal ganglion cells in a mouse model. A 2020 human pilot trial at Columbia showed improvements in visual function in glaucoma patients. An Australian trial found high-dose nicotinamide (3,000 mg per day) improved inner retinal function.

However, the doses used in these glaucoma studies are very high, typically 1,500 to 3,000 mg daily. At those doses, gastrointestinal side effects were reported in up to 31% of participants.

NR, by contrast, has shown strong NAD+ elevation in human studies at 300 mg, with a well-established safety profile. A 2023 study in Nature Communications found NR at 3,000 mg daily for 30 days was safe and produced a pronounced systemic increase in the NAD+ metabolome. A 2024 study in Movement Disorders found long-term NR supplementation over two years was well tolerated and improved neurological outcomes.

The Trade-Off at a Glance

Neither molecule is universally superior. The table below summarizes the key differences based on current research.

So Which One Makes More Sense for Daily Use?

Nicotinamide has a real body of eye-specific human research behind it. That is worth acknowledging. But the doses used in those trials, typically 1,500 to 3,000 mg per day, are far higher than what most people would take as part of a daily wellness routine. At those doses, nearly one in three trial participants experienced gastrointestinal side effects. A supplement you cannot tolerate consistently is not doing its job.

NR's eye health evidence is less mature in humans, and that is also worth acknowledging. Most of the mechanistic work has been done in animal and cell models, and the key human trial (Leung et al., 2022) is still ongoing. But NR achieves meaningful NAD+ elevation at 300 mg, a dose with a clean tolerability record across multiple studies. And because it bypasses the sirtuin inhibition concern associated with high-dose nicotinamide, it supports the full picture of what you are trying to accomplish: not just raising NAD+, but keeping the cellular machinery that depends on NAD+ working properly.

For a strategy meant to be sustained over years, that combination of tolerability, mechanism, and dose practicality makes NR the more sensible daily choice. It is not that nicotinamide is wrong. It is that the version of nicotinamide with meaningful eye health evidence is not the version you can realistically take every day without side effects.

That is the practical distinction, and it is the reason Sight Guard uses NR at 300 mg rather than high-dose nicotinamide.

Key Takeaways

•       Both forms raise NAD+. 

•       Nicotinamide has more direct eye health trial data, but the studied doses are high and come with meaningful side effect rates.

•       NR raises NAD+ effectively at lower, better-tolerated doses and does not appear to inhibit sirtuins the way high-dose nicotinamide can.

•       For a sustainable daily routine, NR's tolerability and mechanistic profile make it the more practical option.

•       The optimal form and dose for eye-specific outcomes is still being studied. Talk to your eye care provider before adding any NAD+ supplement to your routine.